Jefferies upgraded AptarGroup to Buy from Hold with a price target of $215, up from $155. With a strong pipeline of new products such as delivery systems for GLP-1 drugs, for over-the-counter Narcan, and for Neffy, AptarGroup’s Pharma segment will lead an 8.5% annual EBITDA growth through 2026, the analyst tells investors in a research note. The firm expects the stock’s valuation to continue to move towards that of its healthcare packaging competitors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR: